M&As this week: Autobio Diagnostics, MedicaMetrix, Sygnis AG

11 May 2017 (Last Updated May 11th, 2017 18:30)

Diagnostics products developer Autobio Diagnostics plans to invest $29.33m in purchasing 75% stake in Beijing Bio-Top, an in-vitro diagnostics company based in Beijing, China.

Diagnostics products developer Autobio Diagnostics plans to invest $29.33m in purchasing 75% stake in Beijing Bio-Top, an in-vitro diagnostics company based in Beijing, China.

Urological medical devices developer MedicaMetrix will be acquired by Cardiff International in a $6m all-stock transaction.

The target company will merge into Cardiff and will operate as its subsidiary.

The acquisition enables Cardiff, a software systems developer, to enter the medical device field.

Sygnis AG intends to acquire Innova Biosciences for a purchase consideration of approximately $10m, which will be paid through $8.79m in cash and will issue up to 3.5 million shares.

The acquirer company expects the acquisition to strengthen its portfolio with a labelling technology lightning link.

"Sygnis AG expects the acquisition to strengthen its portfolio with a labelling technology lightning link. "

Sygnis is a molecular biology company involved in the development of novel products, while Innova Biosciences offers bioconjugation technologies and services.

Luxendo GmbH has been acquired by Bruker Corporation in a move to expand its fluorescence microscopy portfolio.

Luxendo is engaged in developing advanced single plane illumination microscopes (SPIM), while Bruker is a provider of scientific instruments and diagnostic solutions.

In a $2.99m deal, MG Med intends to acquire 17.1% stake in Oxford Cancer Biomarkers.

MG Med is engaged in molecular diagnostics, while Oxford Cancer Biomarkers is a developer of biomarker diagnostic products.